The Urgent Need for Developing Metallo-β-Lactamase Inhibitors
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".
Deadline for manuscript submissions: closed (1 August 2022) | Viewed by 5862
Special Issue Editors
Interests: antibiotic resistance; protein chemistry; evolution and function of β-lactamases; metallo-β-lactamase inhibitors
Special Issue Information
Dear Colleagues,
The β-lactam class remains the largest class of antibiotics for treating bacterial infections. The widespread use of this class of antibiotics has led to the emergence of different resistance mechanisms, including (a) the production of altered penicillin-binding proteins (PBP) with lower binding affinities for most β-lactam antibiotics and (b) the production of β-lactamases, which is the most common resistance mechanism in Gram-negative bacteria. β-Lactamases can be categorized into serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs). Although SBLs have become more clinically prevalent over the past seventy years, there exist inhibitors, which can be given in combination with β-lactam containing antibiotics to treat bacteria that produce some of the SBLs. However, despite considerable efforts to develop such inhibitors, there are no clinically approved inhibitors available for MBLs, making infections from MBL-producing bacteria a severe challenge. In addition, the COVID-19 crisis further emphasizes the urgency to find MBL inhibitors because co-infections containing SBLs and MBLs have been reported in COVID-19 patients. This Special Issue focuses on characteristics of MBLs and ways to combat their action.
Dr. Zishuo Cheng
Dr. Caitlyn A. Thomas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial resistance
- β-Lactamases
- metallo-β-lactamases
- inhibition
- mechanism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
